Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated (UNH) provides extensive disclosure to investors and regulators through its SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents offer a detailed view of the company’s health care and well-being operations, which span UnitedHealthcare’s health benefit programs and Optum’s health services, technology and analytics businesses.
Annual and quarterly reports describe UnitedHealth Group’s consolidated financial condition and results of operations, as well as segment performance for UnitedHealthcare and Optum. They include information on revenues, earnings from operations, medical costs, operating costs, cash flows, capital structure and risk factors. Investors use these filings to understand how trends in medical utilization, Medicare and Medicaid funding, and pharmacy services affect the company’s financial profile.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have covered topics such as quarterly earnings releases, reaffirmation of earnings outlooks, amendments to bylaws to reflect changes in the company’s registered office and registered agent in Delaware, the appointment of new independent directors, and investor presentations. Some 8-K items are furnished under Regulation FD to share information discussed with investors and analysts, including earnings expectations and the impact of acquisitions like Amedisys.
UnitedHealth Group also files 8-Ks to document governance and leadership changes, including the appointment of directors with regulatory and clinical backgrounds. These filings often reference standard indemnification agreements and compensation arrangements for non-employee directors, providing additional transparency into board practices.
On this SEC filings page, users can review UnitedHealth Group’s regulatory disclosures in one place. Real-time updates from EDGAR ensure that new 10-K, 10-Q and 8-K filings, as well as any amendments, appear promptly. AI-powered summaries can help explain complex sections, highlight key metrics, and clarify the implications of items such as changes in outlook, medical cost trends or bylaw amendments. Investors can also monitor executive and director changes reported on Form 8-K and use the filings history to track how UnitedHealth Group’s strategy, capital management and risk profile evolve over time.
UnitedHealth Group Inc. (UNH) Form 4 filing overview: Director Frederick William McNabb III reported the automatic acquisition of 53 shares of UnitedHealth common stock on 06/24/2025. The shares represent dividend-equivalent units paid on previously vested deferred stock units and were acquired at a stated price of $0.00 under the company’s equity plan.
Following the transaction, McNabb’s direct beneficial ownership increased to 13,709 shares. No derivative securities were bought or sold, and there were no dispositions. The filing was signed by attorney-in-fact Faraz A. Choudhry on 06/26/2025.
The transaction is routine, carries no cash outlay, and does not reflect an open-market purchase. It modestly increases the director’s equity alignment but is immaterial relative to UnitedHealth’s share count and market capitalization.
On 17 June 2025, UnitedHealth Group (UNH) executed an Underwriting and Pricing Agreement with BofA Securities, Barclays, Citigroup and J.P. Morgan to issue $3.0 billion of SEC-registered senior unsecured notes across four tranches: (i) $500 million 4.400% notes due 2028, (ii) $750 million 4.650% notes due 2031, (iii) $1.0 billion 5.300% notes due 2035 and (iv) $750 million 5.950% notes due 2055. The notes settled on 20 June 2025 under the company’s 2008 indenture with U.S. Bank Trust Company as trustee and were issued from automatic shelf registration statement 333-270279.
The 8-K is limited to filing transaction documents: underwriting & pricing agreements (Ex. 1.1-1.2), officers’ certificates & forms of notes (Ex. 4.1-4.4) and the Hogan Lovells legality opinion (Ex. 5.1). No changes to earnings guidance or strategy are disclosed. Proceeds are earmarked for general corporate purposes, providing additional liquidity while modestly increasing leverage and interest expense. By locking in fixed coupons out to 2055, UNH further staggers its maturity ladder at rates consistent with its large-cap investment-grade credit profile.